205646-24-8

Usage

Chemical Classification

Synthetic Cannabinoid

Receptor Interaction

Potent agonist for the CB1 receptor

Derivative of

Indazole-3-carboxamide

Related Compounds

AB-PINACA, ADB-FUBINACA

Use

Sold as a recreational drug

Adverse Effects

Overdose, death, and other negative health effects

Availability

Often found in herbal blends marketed as "legal highs"

Legal Status

Banned in several countries, controlled substance in many jurisdictions due to potential for abuse and harm.

Upstream product

• 205643-28-3 N-benzyl-3-iodo-1H-indazole 
• 100-39-0 benzyl bromide 
• 50264-88-5 indazole-3-carbonitrile 

Relevant academic research and scientific papers

Catalytic cyanation of aryl iodides using DMF and ammonium bicarbonate as the combined source of cyanide: A dual role of copper catalysts

Cu(ii)-catalyzed cyanation of aryl iodides has been developed using DMF and ammonium bicarbonate as the combined source of cyanide. It is assumed that copper is involved both in the generation of CN units from DMF-ammonia and in the cyanation of aryl halides. A range of electron-rich and fused (hetero)aryl iodides underwent cyanation resulting in moderate to good yields.

NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS

The invention relates to 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.

New Somatostatin receptor subtype 4 (SSTR4) agonists

3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.

ANTI-ANGIOGENESIS COMPOUNDS

The present invention provides methods and pharmaceutical compositions for inhibiting expressions of HIF and HIF regulated genes, inhibiting angiogenesis, inducing cell cycle arrest in tumor cells, and treating cell proliferating diseases or conditions

Heterocyclylmethyl-substituted pyrazole derivatives and their use for treating cardiovascular diseases

PCT No. PCT/EP97/05432 Sec. 371 Date Apr. 9, 1999 Sec. 102(e) Date Apr. 9, 1999 PCT Filed Oct. 2, 1997 PCT Pub. No. WO98/16507 PCT Pub. Date Apr. 23, 1998The present invention relates to new heterocyclylmethyl-substituted pyrazole derivatives, processes f